PathAI
its Path-IO (Pathology-driven Immunotherapy Optimization) multimodal platform combines pathomics, radiomics and clinical data to predict immunotherapy response in non-small-cell lung cancer, and its PathAI Discovery platform supports PD-L1 and stromal TIL biomarker development for clinical trials.
- Country
- United States
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| AI pathology interpretation (computational pathology) | diagnostics-medtech | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.